39 research outputs found
Event-free survival curves for atherosclerotic events.
No full textKaplan-Meier curves comparing the risk of (A) composite coronary events and (B) composite ischemic events between the 3 groups. CI, confidence interval; HR, hazard ratio; SGLT2i, sodium-glucose co-transporter 2 inhibitor.</p
Event-free survival curves for HHF and renal events.
No full textKaplan-Meier curves comparing the risk of (A) HHF, (B) composite renal events, and (C) composite HHF and renal events between the 3 groups. CI, confidence interval; HHF, hospitalization for heart failure; HR, hazard ratio; SGLT2i, sodium-glucose co-transporter 2 inhibitor.</p
Changes in laboratory findings.
No full textSerial changes in (A) total cholesterol, (B) LDL cholesterol, (C) HbA1c, and (D) GFR are plotted according to group. GFR, glomerular filtration rate; HbA1c, glycosylated hemoglobin; LDL, low-density lipoprotein; SGLT2i, sodium-glucose co-transporter 2 inhibitor.</p
Study flowchart.
No full textAfter 1:1:2 propensity score matching, there were 921 patients treated with empagliflozin, 921 patients treated with dapagliflozin, and 1,842 patients treated with DPP4i (control group). ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; DPP4i, dipeptidyl peptidase-4 inhibitor; HF, heart failure; SGLT2i, sodium-glucose co-transporter 2 inhibitor.</p
Multivariable predictors of HF and renal events.
No full textMultivariable predictors of HF and renal events.</p
Multivariable predictors of ischemic events.
No full textMultivariable predictors of ischemic events.</p
Additional file 1 of Impact of glycemic control on the progression of aortic stenosis: a single-center cohort study using a common data model
No full textAdditional file 1: Supplementary Table S1. Codes and definitions. Supplementary Table S2. Univariable linear regression analysis for the predictors of AS progression rate. Supplementary Table S3. Univariable logistic regression analysis for the predictors of accelerated AS progression
